What Happened to Vanda Pharmaceuticals Inc.?
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders and other unmet medical needs. The company recently launched NEREUSā¢ for motion sickness and received FDA approval for BYSANTIā¢ for bipolar I disorder and schizophrenia in early 2026, while continuing to navigate regulatory challenges for HETLIOZĀ® in jet lag disorder and expanding its commercial efforts.
Quick Answer
Vanda Pharmaceuticals Inc. has experienced significant developments in early 2026, including the U.S. commercial launch of NEREUSā¢ (tradipitant) for motion sickness and FDA approval for BYSANTIā¢ (milsaperidone) for bipolar I disorder and schizophrenia. Despite a widening net loss in Q1 2026, the company raised its full-year revenue guidance, driven by strong FanaptĀ® sales growth and anticipated contributions from new products. Vanda is also pursuing a rare public FDA hearing regarding its HETLIOZĀ® application for jet lag disorder after a second refusal in January 2026.
šKey Facts
š Complete Timeline14 events
HETLIOZĀ® Receives First FDA Approval
HETLIOZĀ® (tasimelteon) was first approved by the FDA for the treatment of Non-24-Hour Sleep-Wake Disorder in adults.
FDA First Rejects HETLIOZĀ® for Jet Lag Disorder
Vanda Pharmaceuticals initially sought FDA approval for HETLIOZĀ® to treat jet lag disorder, but the application was rejected.
HETLIOZĀ® Indication Expanded for Smith-Magenis Syndrome
The FDA expanded the indication for HETLIOZĀ® to include nighttime sleep disturbances associated with Smith-Magenis Syndrome.
Vanda Files Lawsuit Against FDA Over HETLIOZĀ® for Jet Lag
Vanda Pharmaceuticals filed a lawsuit against the FDA following the continued refusal to approve HETLIOZĀ® for jet lag disorder.
Court Orders FDA to Review HETLIOZĀ® or Hold Hearing
A District of Columbia court ordered the FDA to either review Vanda's application for HETLIOZĀ® in jet lag disorder or hold a hearing.
Federal Appeals Court Overturns FDA Refusal for HETLIOZĀ®
A federal appeals court set aside the FDA's earlier refusal to approve HETLIOZĀ® for jet lag disorder, remanding the case to the agency.
Collaborative Framework Agreement with FDA for HETLIOZĀ®
Vanda announced a collaborative framework agreement with the FDA for an expedited re-review of the HETLIOZĀ® sNDA for jet lag disorder.
FDA Approves NEREUSā¢ (tradipitant)
The FDA approved NEREUSā¢ (tradipitant) for the prevention of vomiting induced by motion in adults.
FDA Issues Second Refusal Letter for HETLIOZĀ® Jet Lag sNDA
The FDA issued a decision letter concluding that the sNDA for HETLIOZĀ® for jet lag disorder could not be approved in its current form, despite acknowledging positive efficacy.
FDA Approves BYSANTIā¢ (milsaperidone)
BYSANTIā¢ (milsaperidone) received FDA approval for the treatment of bipolar I disorder and schizophrenia.
FDA Grants Landmark Public Hearing for HETLIOZĀ® Jet Lag
The FDA granted Vanda's request for a formal evidentiary public hearing to review the proposed refusal of HETLIOZĀ® for jet lag disorder, a rare event not seen in over 40 years for drug approvals.
NEREUSā¢ (tradipitant) Commercial Availability in U.S.
Vanda announced the U.S. commercial availability of NEREUSā¢ (tradipitant) for motion sickness, launched via a direct-to-consumer platform.
Reports Q1 2026 Financial Results and Raises Full-Year Guidance
Vanda Pharmaceuticals reported Q1 2026 net product sales of $51.7 million and a net loss of $48.6 million, while raising its full-year 2026 revenue guidance to $240-$290 million.
PDUFA Target Action Date for Imsidolimab BLA
The FDA's Prescription Drug User Fee Act (PDUFA) target action date for the imsidolimab Biologics License Application (BLA) for Generalized Pustular Psoriasis is set for this date.
šDeep Dive Analysis
Vanda Pharmaceuticals Inc. has been actively shaping its product portfolio and commercial strategy in early 2026, marked by both new product introductions and ongoing regulatory battles. The company reported its first-quarter 2026 financial results on May 6, 2026, indicating total net product sales of $51.7 million, a 3% increase compared to Q1 2025. While FanaptĀ® sales showed robust growth, increasing 26% year-over-year to $29.6 million, sales of HETLIOZĀ® declined by 24% to $15.9 million, partly due to generic competition.
A significant milestone in early 2026 was the U.S. commercial launch of NEREUSā¢ (tradipitant) in May, following its FDA approval on December 30, 2025. NEREUSā¢ is the first new prescription medicine for the prevention of vomiting induced by motion in over 40 years and is being distributed through an innovative direct-to-consumer platform, nereus.us. Additionally, Vanda received FDA approval for BYSANTIā¢ (milsaperidone) on February 20, 2026, for the treatment of bipolar I disorder and schizophrenia, further expanding its central nervous system franchise.
Despite these commercial successes, Vanda's net loss widened to $48.6 million in Q1 2026, compared to $29.5 million in Q1 2025, primarily due to increased selling, general, and administrative expenses associated with new product launches and an expanded sales force. The company's cash, cash equivalents, and marketable securities stood at $202.3 million as of March 31, 2026. Looking ahead, Vanda raised its full-year 2026 revenue guidance to $240-$290 million, incorporating expected contributions from NEREUSā¢.
Another key turning point involves HETLIOZĀ® (tasimelteon) for jet lag disorder. After a D.C. Circuit Court ruling in August 2025 that set aside a prior FDA refusal, Vanda and the FDA entered a collaborative framework. However, on January 8, 2026, the FDA again issued a decision letter stating the supplemental New Drug Application (sNDA) could not be approved in its current form, citing that clinical trial protocols were not sufficiently analogous to actual jet travel. Vanda strongly disagreed with this interpretation and, in a rare move, the FDA granted Vanda's request for a formal evidentiary public hearing on March 3, 2026, to review the proposed refusal. This marks a significant procedural victory for Vanda, as such hearings have not been held for drug approvals in over 40 years.
As of May 10, 2026, Vanda Pharmaceuticals is actively commercializing its newly approved products, NEREUSā¢ and BYSANTIā¢, while continuing to advocate for HETLIOZĀ® for jet lag disorder through the unprecedented FDA public hearing process. The company's pipeline also includes imsidolimab, with a Biologics License Application (BLA) for Generalized Pustular Psoriasis accepted for FDA review and a PDUFA target action date of December 12, 2026. Analyst sentiment remains cautiously optimistic, with a consensus rating of "Moderate Buy" and an average 12-month price target of $14.90.
What If...?
Explore alternate histories. What if Vanda Pharmaceuticals Inc. made different choices?